Mitochondria in the striatum of subjects with schizophrenia: Relationship to treatment response

Synapse

Volumn 65, Issue 3, 2011, Pages 215-224

  Somerville, Shahza M ^a,b   Lahti, Adrienne C ^c   Conley, Robert R ^b,d   Roberts, Rosalinda C ^c  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Lilly Technology Center   (United States)

Author keywords

Antipsychotic drugs; Postmortem; Synapses; Treatment resistance

Indexed keywords

ADULT; ARTICLE; AUTOPSY; BRAIN TISSUE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; ELECTRON MICROSCOPY; ENERGY YIELD; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MITOCHONDRION; NEUROPIL; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA; STEREOLOGY; SYNAPSE; TREATMENT RESPONSE;

EID: 78650665988     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20838     Document Type: Article

References (85)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M. 1998. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 155: 761-767.
2. Altamura AC, Bassetti R, Cattaneo E, Vismara S. 2005. Some biological correlates of drug resistance in schizophrenia: A multidimensional approach. World J Biol Psychiatry Suppl 2: 23-30.
3. Arango C, Breier A, McMahon R, Carpenter WTJr, Buchanan RW. 2003. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry 160: 1421-1427.
4. Beerpoot LJ, Lipska BK, Weinberger DR. 1996. Neurobiology of treatment-resistant schizophrenia: New insights and new models. Eur Neuropsychopharmacol 6: S27-S34.
5. Ben-Shachar D. 2002. Mitochondrial dysfunction in schizophrenia: A possible linkage to dopamine. J Neurochem 83: 1241-1251.
6. Ben-Shachar D, Laifenfeld D. 2004. Mitochondria, synaptic plasticity, and schizophrenia. Int Review Neurobiol 59: 273-296.
7. Ben-Shachar D, Karry R. 2008. Neuroanatomical Pattern of Mitochondrial Complex I Pathology Varies between Schizophrenia, Bipolar Disorder and Major Depression. PLoS ONE 3: e3676.
8. Bilder RM, Wu H, Chakos MH, Bogerts B, Pollack S, Aronowitz J, Ashtari M, Degreef G, Kane JM, Lieberman JA. 1994. Cerebral morphometry and clozapine treatment in schizophrenia. J Clin Psychiatry 55: 53-56.
9. Buchsbaum MS, Potkin SG, Siegel BVJr, Lohr J, Katz M, Gottschalk LA, Gulasekaram B, Marshall JF, Lottenberg S, Teng CY. 1992. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 49: 966-974.
10. Buchsbaum MS, Shihabuddin L, Brickman AM, Miozzo R, Prikryl R, Shaw R, Davis K. 2003. Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophr Res 64: 53-62.
11. Carlsson A. 1978. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135: 165-173.
12. Carlsson A, Lindqvist M. 1963. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140-144.
13. Cavelier L, Jazin EE, Eriksson I, Prince J, Bave U, Oreland L, Gyllensten U. 1995. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics 29: 217-224.
14. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M. 1994. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 151: 1430-1436.
15. Chang DT, Reynolds IJ. 2006. Mitochondrial trafficking and morphology in healthy and injured neurons. Prog Neurobiol 80: 241-268.
16. Conley RR, Kelly DL. 2000. Pharmacologic treatment of schizophrenia, 1st ed. Professional Communications.
17. Conley RR, Kelly DL. 2001. Management of treatment resistance in schizophrenia. Biol Psychiatry 50: 898-911.
18. 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 29: 629-634.
19. Duchen MR, Verkhratsky A, Muallem S. 2008. Mitochondria and calcium in health and disease. Cell Calcium 44: 1-5.
20. Geinisman Y, Gundersen HJ, van der Zee E, West MJ. 1996. Unbiased stereological estimation of the total number of synapses in a brain region. J Neurocytol 25: 805-819.
21. Gemmell HG, Evans NT, Besson JA, Roeda D, Davidson J, Dodd MG, Sharp PF, Smith FW, Crawford JR, Newton RHKulkarni V, Mallard JR. 1990. Regional cerebral blood flow imaging: A quantitative comparison of technetium-99m-HMPAO SPECT with C15O2 PET. J Nucl Med 31: 1595-1600.
22. Goff DC, Coyle JT. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377.
23. Gunduz H, Wu H, Ashtari M, Bogerts B, Crandall D, Robinson DG, Alvir J, Lieberman J, Kane J, Bilder R. 2002. Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects. Biol Psychiatry 51: 801-808.
24. Gunter TE, Gunter KK, Sheu SS, Gavin CE. 1994. Mitochondrial calcium transport: Physiological and pathological relevance. Am J Physiol 267: 313-339.
25. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. 1998. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 155: 1711-1717.
26. Harrison PJ. 1999. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122: 593-624.
27. Harrison PJ, Weinberger DR. 2005. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 10: 40-68.
28. Harrison PJ, Heath PR, Eastwood SL, Burnet PW, McDonald B, Pearson RC. 1995. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: Selective mRNA vulnerability and comparison with their encoded proteins. Neurosci Lett 200: 151-154.
29. Isaacs KR, Anderson BJ, Alcantara AA, Black JE, Greenough WT. 1992. Exercise and the brain: Angiogenesis in the adult rat cerebellum after vigorous physical activity and motor skill learning. J Cereb Blood Flow Metab 12: 110-119.
30. Jentsch JD, Roth RH. 1999. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-25.
31. Johnson SA, Morgan DG, Finch CE. 1986. Extensive postmortem stability of RNA from rat and human brain. J Neurosci Res 16: 267-80.
32. Johnston NL, Cervenak J, Shore AD, Torrey EF, Yolken RH. 1997. Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR. Stanley Neuropathology Consortium. J Neurosci Methods 77: 83-92.
33. Kane JM, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24: 62-67.
34. Kane JM, Assunção-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT. 2008. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials. Schizophr Res 105: 208-215.
35. Karry R, Klein E, Ben Shachar D. 2004. Mitochondrial complex I subunits expression is altered in schizophrenia: A postmortem study. Biol Psychiatry 55: 676-684.
36. Kolomeets NS, Uranova N. 2009. Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: A postortem (sic) morphometric study. World J Biol Psych 9: 1-11.
37. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MBJr, Charney DS. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
38. Kung L, Roberts RC. 1999. Mitochondrial pathology in human schizophrenic striatum: A postmortem ultrastructural study. Synapse 31: 67-75.
39. Kvajo M, Dhilla A, Swor DE, Karayiorgou M, Gogos JA. 2008. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol Psychiatry 13: 685-696.
40. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. 1995. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6: 869-872.
41. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
42. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci 93: 9235-9240.
43. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. 1999. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 46: 56-72.
44. Lewis DA, Lieberman JA. 2000. Catching up on schizophrenia: Natural history and neurobiology. Neuron 28: 325-334.
45. Li Z, Okamoto K, Hayashi Y, Sheng M. 2004. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119: 873-887.
46. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
47. Ligon LA, Steward O. 2000. Role of microtubules and actin filaments in the movement of mitochondria in the axons and dendrites of cultured hippocampal neurons. J Comp Neurol 427: 351-361.
48. Marchbanks RM, Ryan M, Day IN, Owen M, McGuffin P, Whatley SA. 2003. A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr Res 65: 33-38.
49. Maurer I, Moller HJ. 1997. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 174: 255-259.
50. Maurer I, Zierz S, Moller H. 2001. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 48: 125-136.
51. McEvoy JP. 2006. An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr 11: 4-8.
52. Miller KE, Sheetz MP. 2004. Axonal mitochondrial transport and potential are correlated. J Cell Sci 117: 2791-2804.
53. Mitelman SA, Shihabuddin L, Brickman AM, Hazlett EA, Buchsbaum MS. 2005. Volume of the cingulate and outcome in schizophrenia. Schizophr Res 72: 91-108.
54. Mitelman SA, Canfield EL, Chu KW, Brickman AM, Shihabuddin L, Hazlett EA, Buchsbaum MS. 2009. Poor outcome in chronic schizophrenia is associated with progressive loss of volume of the putamen. Schizophr Res 113: 241-245.
55. Mjaatvedt AE, Wong-Riley MT. 1988. Relationship between synaptogenesis and cytochrome oxidase activity in Purkinje cells of the developing rat cerebellum. J Comp Neurol 277: 155-182.
56. Perez-Costas E, Melendez-Ferro M, Roberts R. 2007. Microscopy techniques and the study of synapses. In: Mendez-Vilas A, Diaz J, editors. Modern research and educational topics in microscopy, Vol. 1. Badajoz: Spain Formatex. p 164-170.
57. Powers RE. 1999. The neuropathology of schizophrenia. J Neuropathol Exp Neurol 58: 679-690.
58. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S. 2004. Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-97.
59. Prince JA, Yassin MS, Oreland L. 1997. Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine. Neuropharmacology 36: 1665-1678.
60. Prince JA, Blennow K, Gottfries CG, Karlsson I, Oreland L. 1999. Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology 21: 372-379.
61. Prince JA, Harro J, Blennow K, Gottfries CG, Oreland L. 2000. Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics. Neuropsychopharmacology 22: 284-292.
62. Resnick SM, Gur RE, Alavi A, Gur RC, Reivich M. 1988. Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Res 24: 1-11.
63. Roberts RC, Conley R, Kung L, Peretti FJ, Chute DJ. 1996. Reduced striatal spine size in schizophrenia: A postmortem ultrastructural study. NeuroReport 7: 1214-1218.
64. Roberts RC, Roche JK, Conley RR. 2005a. Synaptic differences in the postmortem striatum of subjects with schizophrenia: A stereological ultrastructural analysis. Synapse 56: 185-197.
65. Roberts RC, Roche JK, Conley RR. 2005b. Synaptic differences in the patch matrix compartments of subjects with schizophrenia: A postmortem ultrastructural study of the striatum. Neurobiol Dis 20: 324-335.
66. Roberts RC, Roche JK, Conley RR. 2008. Differential synaptic changes in the striatum of subjects with undifferentiated versus paranoid schizophrenia. Synapse 62: 616-627.
67. Roberts RC, Roche JK, Conley RR, Lahti AC. 2009. Dopaminergic synapses in the caudate of subjects with schizophrenia: Relationship to treatment response. Synapse 63: 520-530.
68. Rodriguez VM, Andree RM, Castejon MJ, Zamora ML, Alvaro PC, Delgado JL, Vila FJ. 1997. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res 76: 51-61.
69. Salzman S, Endicott J, Clayton P, Winokur G. 1983. Diagnostic evaluation after death (DEAD). In National Institute of Mental Health, Neuroscience Research Branch, Rockville, MD.
70. Sheitman BB, Lieberman JA. 1998. The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res 32: 143-150.
71. Shihabuddin L, Buchsbaum MS, Hazlett EA, Haznedar MM, Harvey PD, Newman A, Schnur DB, Spiegel-Cohen J, Wei T, Machac J, Knesaurek K, Vallabhajosula S, Biren MA, Ciaravolo TM, Luu-Hsia C. 1998. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatry 55: 235-243.
72. Somerville SM, Roche JK, Conley RR, Roberts RC. 2003. Ultrastructural study of mitochondria in postmortem striatal patch and matrix compartments in schizophrenia. Soc Neurosci Abstr 29: 316.3.
73. Spitzer RL, Williams JB, Gibbon M, First MB. 1992. The Structured Clinical Interview for DSM-III-R (SCID). I. History, rationale, and description. Arch Gen Psychiatry 49: 624-629.
74. Staal WG, Hulshoff Pol HE, Schnack HG, van Haren NE, Seifert N, Kahn RS. 2001. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am J Psychiatry 158: 1140-1142.
75. Stan AD, Ghose S, Gao X-M, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ, Tamminga CA. 2006. Human postmortem tissue: What quality markers matter? Brain Res 1123: 1-11.
76. Sterio DC. 1984. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 134: 127-136.
77. Stern RG, Kahn RS, Harvey PD, Amin F, Apter SH, Hirschowitz J. 1993. Early response to haloperidol treatment in chronic schizophrenia. Schizophr Res 10: 165-171.
78. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. 1999. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446.
79. Tomiyama G. 1990. Chronic schizophrenia-like states in methamphetamine psychosis. Jpn J Psychiatry Neurol 44: 531-539.
80. Turkington TG, Jaszczak RJ, Pelizzari CA, Harris CC, MacFall JR, Hoffman JM, Coleman RE. 1993. Accuracy of registration of PET. SPECT and MR images of a brain phantom. J Nucl Med 34: 1587-1594.
81. Uranova NA, Casanova MF, DeVaughn NM, Orlovskaya DD, Denisov DV. 1996. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients. Schizophr Res 22: 81-83.
82. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V. 2001. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 55: 597-610.
83. Uranova NA, Vostrikiv VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. 2007. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharm 10: 537-545.
84. Wiesel FA, Wik G, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S. 1987. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates. Acta Psychiatr Scand 76: 628-641.
85. Wong-Riley MT. 1989. Cytochrome oxidase: An endogenous metabolic marker for neuronal activity. Trends Neurosci 12: 94-101.